MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view
Year: 2023
Type: review
Abstract: Increasing evidence suggests that patients with diabetes, particularly type 2 diabetes (T2D), are characterized by an increased risk of developing different types of cancer, so cancer could be proposed as a new T2D-related complication. On the other hand, cancer may also increase the risk of developing new-onset diabetes, mainly caused by anticancer therapies. Hyperinsulinemia, hyperglycemia, and chronic inflammation typical of T2D could represent possible mechanisms involved in cancer development in diabetic patients. MicroRNAs (miRNAs) are a subset of non-coding RNAs, ⁓22 nucleotides in length, which control the post-transcriptional regulation of gene expression through both translational repression and messenger RNA degradation. Of note, miRNAs have multiple target genes and alteration of their expression has been reported in multiple diseases, including T2D and cancer. Accordingly, specific miRNA-regulated pathways are involved in the pathogenesis of both conditions. In this review, a panel of experts from the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF) provide a critical view of the evidence about the involvement of miRNAs in the pathophysiology of both T2D and cancer, trying to identify the shared miRNA signature and pathways able to explain the strong correlation between the two conditions, as well as to envision new common pharmacological approaches.
Source: ESMO Open
Authors: A. Natalicchio, M. Montagnani, M. Gallo, N. Marrano, A. Faggiano, M.C. Zatelli, R. Mazzilli, A. Argentiero, R. Danesi, S. D’Oronzo, S. Fogli, D. Giuffrida, S. Gori, A. Ragni, V. Renzelli, A. Russo, T. Franchina, E. Tuveri, L. Sciacca, M. Monami, G. Cirino, G. Di Cianni, A. Colao, A. Avogaro, S. Cinieri, N. Silvestris, F. Giorgino
Institutions: University of Bari Aldo Moro, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, University of Ferrara, Istituto Tumori Bari, University of Pisa, Ospedale Sacro Cuore Don Calabria, University of Palermo, University of Messina, University of Catania, Azienda Ospedaliero-Universitaria Careggi, University of Florence, University of Naples Federico II, Ospedale di Livorno, Federico II University Hospital, University of Padua, Ospedale A. Perrino
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W4378902158